Katheryn Meek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Katheryn Meek has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Mauro Modesti
Aix Marseille Universite
8 shared publications Jessica A. Neal
College of Veterinary Medicine, Department of Microbiology & Molecular Genetics, Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA
6 shared publicationsSusan P. Lees-Miller
Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada
6 shared publicationsPauline Douglas
Departments of Biochemistry & Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada T2N4N1
4 shared publications- Amanda K. Chaplin
Leicester Institute for Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, UK
3 shared publications Mariia Mikhova
Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI, U.S.A
3 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Targeting Artemis sensitizes acute lymphoblastic leukemia cells to topoisomerase 2 poisons by disrupting DNA-PKcs-dependent repair
Topoisomerase 2 (Top2) poisons are widely used in cancer therapy but are associated with toxicity and secondary malignancies. Top2 adduct removal requires endonuclease activity prior to repair of the resulting DNA double-strand break (DSB). We show that the non-homologous end joining (NHEJ) enzyme Artemis is a key player in the process and a major target for treatment of human B-cell acute lymphoblastic leukemia (ALL). An Artemis knockout is sensitive to etoposide treatment at nanomolar levels and has significantly more unrepaired DNA DSBs. Inhibition of the Artemis activator, DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs), acts synergistically with Top2 poisons to further sensitize ALL cells. Genetic loss of Artemis ablates this synergy underscoring its critical role in this drug interaction. Furthermore, Artemis loss results in a significant accumulation of covalent Top2A DNA adducts following etoposide treatment and a significant increase in unrepaired DNA DSBs. As clinical data demonstrate that high Artemis expression correlates with poor survival in several cancers, our work may unlock new avenues for the treatment of aggressive cancers.
- 21 August 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessTargeting Artemis sensitizes acute lymphoblastic leukemia cells to topoisomerase 2 poisons by disrupting DNA-PKcs-dependent repair
Topoisomerase 2 (Top2) poisons are widely used in cancer therapy but are associated with toxicity and secondary malignancies. Top2 adduct removal requires endonuclease activity prior to repair of the resulting DNA double-strand break (DSB). We show that the non-homologous end joining (NHEJ) enzyme Artemis is a key player in the process and a major target for treatment of human B-cell acute lymphoblastic leukemia (ALL). An Artemis knockout is sensitive to etoposide treatment at nanomolar levels and has significantly more unrepaired DNA DSBs. Inhibition of the Artemis activator, DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs), acts synergistically with Top2 poisons to further sensitize ALL cells. Genetic loss of Artemis ablates this synergy underscoring its critical role in this drug interaction. Furthermore, Artemis loss results in a significant accumulation of covalent Top2A DNA adducts following etoposide treatment and a significant increase in unrepaired DNA DSBs. As clinical data demonstrate that high Artemis expression correlates with poor survival in several cancers, our work may unlock new avenues for the treatment of aggressive cancers.
- Open Access
- 24 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cryo-EM structures of NHEJ assemblies with nucleosomes
DNA double-strand breaks (DSBs) are highly deleterious lesions that can trigger cell death or carcinogenesis if unrepaired or misrepaired. In mammals, most DSBs are repaired by non-homologous end joining (NHEJ), which begins when Ku70/80 binds DNA ends and recruits DNA-PKcs to form the DNA-PK holoenzyme. Although recent cryo-EM studies have resolved several NHEJ assemblies, how these factors access DSBs within nucleosomes remains unclear. Here, we present cryo-EM structures of human Ku70/80 and DNA-PK bound to nucleosomes. Ku70/80 binds the DNA end and bends it away from the nucleosome core, while the Ku70 C-terminal SAP domain makes an additional, specific DNA contact. Our DNA-PK–nucleosome structure further reveals the opening of the Ku80 vWA domain, and we show that non-hydrolysable ATP promotes synapsis by stabilising the Ku80-mediated DNA-PK dimer. These structures reveal a model for DSB recognition on nucleosomal DNA and provide insights relevant to targeting NHEJ in cancer therapy.
- 24 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCryo-EM structures of NHEJ assemblies with nucleosomes
DNA double-strand breaks (DSBs) are highly deleterious lesions that can trigger cell death or carcinogenesis if unrepaired or misrepaired. In mammals, most DSBs are repaired by non-homologous end joining (NHEJ), which begins when Ku70/80 binds DNA ends and recruits DNA-PKcs to form the DNA-PK holoenzyme. Although recent cryo-EM studies have resolved several NHEJ assemblies, how these factors access DSBs within nucleosomes remains unclear. Here, we present cryo-EM structures of human Ku70/80 and DNA-PK bound to nucleosomes. Ku70/80 binds the DNA end and bends it away from the nucleosome core, while the Ku70 C-terminal SAP domain makes an additional, specific DNA contact. Our DNA-PK–nucleosome structure further reveals the opening of the Ku80 vWA domain, and we show that non-hydrolysable ATP promotes synapsis by stabilising the Ku80-mediated DNA-PK dimer. These structures reveal a model for DSB recognition on nucleosomal DNA and provide insights relevant to targeting NHEJ in cancer therapy.
- Open Access
Ku limits aberrant mRNA splicing promoted by intronic antisense Alu elements
SUMMARY: Alu elements are short repeats that occupy approximately 10% of the human genome. The enrichment of primate genomes with Alu sequences occurred at the prosimian/new-world monkey evolutionary juncture, which coincided with a substantial increase in the expression levels of the Ku70/80 heterodimer. Previous work suggests that the elevated levels of Ku70/80 are required to prevent the activation of innate immune signaling pathways triggered by RNA molecules derived from Alu elements. Here we demonstrate that Ku regulates mRNA splicing, by inhibiting the use of alternative splice sites contained in intronic antisense Alu elements. Dysregulation of splicing precedes cell death and impacts genes involved in essential RNA metabolism processes, including splicing and ribosome biogenesis, likely impacting cell viability. We propose a model in which Ku binding of antisense Alu elements in introns of mRNAs modulates the use of alternative splice sites to balance beneficial and detrimental contributions of Alu repeats within primate genomes.
Open AccessKu limits aberrant mRNA splicing promoted by intronic antisense Alu elements
SUMMARY: Alu elements are short repeats that occupy approximately 10% of the human genome. The enrichment of primate genomes with Alu sequences occurred at the prosimian/new-world monkey evolutionary juncture, which coincided with a substantial increase in the expression levels of the Ku70/80 heterodimer. Previous work suggests that the elevated levels of Ku70/80 are required to prevent the activation of innate immune signaling pathways triggered by RNA molecules derived from Alu elements. Here we demonstrate that Ku regulates mRNA splicing, by inhibiting the use of alternative splice sites contained in intronic antisense Alu elements. Dysregulation of splicing precedes cell death and impacts genes involved in essential RNA metabolism processes, including splicing and ribosome biogenesis, likely impacting cell viability. We propose a model in which Ku binding of antisense Alu elements in introns of mRNAs modulates the use of alternative splice sites to balance beneficial and detrimental contributions of Alu repeats within primate genomes.
- Open Access
- 19 June 2025
- Published by Springer Nature in Research Square
Targeting Artemis Sensitizes B Cells to Topoisomerase 2 Poisons by Disrupting DNA-PKcs-Dependent Repair
Topoisomerase 2 (Top2) poisons are widely used in cancer therapy but are associated with toxicity and secondary malignancies. Removing Top2 adducts requires endonuclease activity and repair by non-homologous end joining (NHEJ). We show that the NHEJ enzyme Artemis is a promising target for co-treatment with Top2 poisons. Inhibition of the Artemis activator, DNA-PKcs, with peposertib (M3814) sensitizes B cells to Top2 poisons while ATM or ATR inhibition does not. Interestingly, while M3814 treatment blocks Artemis endonuclease activity, Artemis phosphorylation is still detectible and is only affected upon inhibiting ATM, suggestive of an additional role for Artemis in DNA damage response signaling. Additionally, Artemis loss results in a significant accumulation of Top2 DNA adducts following treatment, indicating Artemis may act outside its canonical role in NHEJ to reduce adduct burden. Clinical data demonstrates that high Artemis expression correlates with poor survival in several cancers, and we demonstrate that Artemis function is critical for survival following combination drug treatment. These insights can be leveraged to unlock new avenues for the treatment of aggressive cancers by enhancing the cytotoxicity of agents through blockade of DNA break repair.
- 19 June 2025
- Published by Springer Nature in Research Square
Open AccessTargeting Artemis Sensitizes B Cells to Topoisomerase 2 Poisons by Disrupting DNA-PKcs-Dependent Repair
Topoisomerase 2 (Top2) poisons are widely used in cancer therapy but are associated with toxicity and secondary malignancies. Removing Top2 adducts requires endonuclease activity and repair by non-homologous end joining (NHEJ). We show that the NHEJ enzyme Artemis is a promising target for co-treatment with Top2 poisons. Inhibition of the Artemis activator, DNA-PKcs, with peposertib (M3814) sensitizes B cells to Top2 poisons while ATM or ATR inhibition does not. Interestingly, while M3814 treatment blocks Artemis endonuclease activity, Artemis phosphorylation is still detectible and is only affected upon inhibiting ATM, suggestive of an additional role for Artemis in DNA damage response signaling. Additionally, Artemis loss results in a significant accumulation of Top2 DNA adducts following treatment, indicating Artemis may act outside its canonical role in NHEJ to reduce adduct burden. Clinical data demonstrates that high Artemis expression correlates with poor survival in several cancers, and we demonstrate that Artemis function is critical for survival following combination drug treatment. These insights can be leveraged to unlock new avenues for the treatment of aggressive cancers by enhancing the cytotoxicity of agents through blockade of DNA break repair.
- Open Access
- 14 December 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (2)
Lig3-dependent rescue of mouse viability and DNA double-strand break repair by catalytically inactive Lig4
Recent studies have revealed a structural role for DNA ligase 4 (Lig4) in the maintenance of a repair complex during non-homologous end joining (NHEJ) of DNA double-strand breaks. In cultured cell lines, catalytically inactive Lig4 can partially alleviate the severe DNA repair phenotypes observed in cells lacking Lig4. To study the structural role of Lig4 in vivo, a mouse strain harboring a point mutation to Lig4’s catalytic site was generated. In contrast to the ablation of Lig4, catalytically inactive Lig4 mice are born alive. These mice display marked growth retardation and have clear deficits in lymphocyte development. We considered that the milder phenotype results from inactive Lig4 help to recruit another ligase to the repair complex. We next generated a mouse strain deficient for nuclear Lig3. Nuclear Lig3-deficient mice are moderately smaller and have elevated incidences of cerebral ventricle dilation but otherwise appear normal. Strikingly, in experiments crossing these two strains, mice lacking nuclear Lig3 and expressing inactive Lig4 were not obtained. Timed mating revealed that fetuses harboring both mutations underwent resorption, establishing an embryonic lethal genetic interaction. These data suggest that Lig3 is recruited to NHEJ complexes to facilitate end joining in the presence (but not activity) of Lig4.
- 14 December 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (2)
Open AccessLig3-dependent rescue of mouse viability and DNA double-strand break repair by catalytically inactive Lig4
Recent studies have revealed a structural role for DNA ligase 4 (Lig4) in the maintenance of a repair complex during non-homologous end joining (NHEJ) of DNA double-strand breaks. In cultured cell lines, catalytically inactive Lig4 can partially alleviate the severe DNA repair phenotypes observed in cells lacking Lig4. To study the structural role of Lig4 in vivo, a mouse strain harboring a point mutation to Lig4’s catalytic site was generated. In contrast to the ablation of Lig4, catalytically inactive Lig4 mice are born alive. These mice display marked growth retardation and have clear deficits in lymphocyte development. We considered that the milder phenotype results from inactive Lig4 help to recruit another ligase to the repair complex. We next generated a mouse strain deficient for nuclear Lig3. Nuclear Lig3-deficient mice are moderately smaller and have elevated incidences of cerebral ventricle dilation but otherwise appear normal. Strikingly, in experiments crossing these two strains, mice lacking nuclear Lig3 and expressing inactive Lig4 were not obtained. Timed mating revealed that fetuses harboring both mutations underwent resorption, establishing an embryonic lethal genetic interaction. These data suggest that Lig3 is recruited to NHEJ complexes to facilitate end joining in the presence (but not activity) of Lig4.
- Open Access
- 23 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Single-molecule imaging reveals the kinetics of non-homologous end-joining in living cells
Non-homologous end joining (NHEJ) is the predominant pathway that repairs DNA double-stranded breaks (DSBs) in vertebrates. However, due to challenges in detecting DSBs in living cells, the repair capacity of the NHEJ pathway is unknown. The DNA termini of many DSBs must be processed to allow ligation while minimizing genetic changes that result from break repair. Emerging models propose that DNA termini are first synapsed ~115 Å apart in one of several long-range synaptic complexes before transitioning into a short-range synaptic complex that juxtaposes DNA ends to facilitate ligation. The transition from long-range to short-range synaptic complexes involves both conformational and compositional changes of the NHEJ factors bound to the DNA break. Importantly, it is unclear how NHEJ proceeds in vivo because of the challenges involved in analyzing recruitment of NHEJ factors to DSBs over time in living cells. Here, we develop an approach to study the temporal and compositional dynamics of NHEJ complexes using live cell single-molecule imaging. Our results provide direct evidence for stepwise maturation of the NHEJ complex, pinpoint key regulatory steps in NHEJ progression, and allowed us to estimate the overall repair capacity of the NHEJ pathway in living cells.
- 23 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessSingle-molecule imaging reveals the kinetics of non-homologous end-joining in living cells
Non-homologous end joining (NHEJ) is the predominant pathway that repairs DNA double-stranded breaks (DSBs) in vertebrates. However, due to challenges in detecting DSBs in living cells, the repair capacity of the NHEJ pathway is unknown. The DNA termini of many DSBs must be processed to allow ligation while minimizing genetic changes that result from break repair. Emerging models propose that DNA termini are first synapsed ~115 Å apart in one of several long-range synaptic complexes before transitioning into a short-range synaptic complex that juxtaposes DNA ends to facilitate ligation. The transition from long-range to short-range synaptic complexes involves both conformational and compositional changes of the NHEJ factors bound to the DNA break. Importantly, it is unclear how NHEJ proceeds in vivo because of the challenges involved in analyzing recruitment of NHEJ factors to DSBs over time in living cells. Here, we develop an approach to study the temporal and compositional dynamics of NHEJ complexes using live cell single-molecule imaging. Our results provide direct evidence for stepwise maturation of the NHEJ complex, pinpoint key regulatory steps in NHEJ progression, and allowed us to estimate the overall repair capacity of the NHEJ pathway in living cells.
- 8 August 2024
- Published by Elsevier in DNA Repair
- Vol. 142, 103737
Compared to other NHEJ factors, DNA-PK protein and RNA levels are markedly increased in all higher primates, but not in prosimians or other mammals
- 8 August 2024
- Published by Elsevier in DNA Repair
- Vol. 142, 103737
Compared to other NHEJ factors, DNA-PK protein and RNA levels are markedly increased in all higher primates, but not in prosimians or other mammals
- Open Access
- 13 December 2023
- Published by Springer Nature in Research Square
Unravelling the complexities of DNA-PK activation by structure-based mutagenesis.
It has been known for decades that the DNA-dependent protein kinase (DNA-PK) is only an active serine/threonine protein kinase when it is bound to a DNA double-stranded end; still, the molecular details of how this activation is achieved have remained elusive. The recent surge in structural information for DNA-PK complexes has provided valuable insights into the process of DNA end recognition by DNA-PK. A particularly intriguing feature of this kinase is a region of the protein that can transition from a seemingly structurally disordered state to a single alpha-helix that traverses down the DNA binding cradle. The DNA-PK bound DNA end of the DNA substrate engages with and appears to split around this helix which has been named the DNA End Blocking helix (DEB). Here a mutational approach is utilized to clarify the role of the DEB, and how DNA ends activate the enzyme. Our data suggest two distinct methods of kinase activation that is dependent on the DNA end chemistry. If the DNA end can split around the helix and stabilize the interaction between the DNA end and the DEB with a recently defined Helix-Hairpin-Helix (HHH) motif, the kinase forms an end-protection monomer that is active towards DNA-PK's many substrates. But if the DNA end cannot stably interact with the DEB [because of the DNA end structure, for instance hairpins, or because the DEB has been disrupted by mutation], the kinase is only partially activated, resulting in specific autophosphorylations of the DNA-PK monomer that allows nucleolytic end-processing. We posit that mutants that disrupt the capacity to stably generate the DEB/HHH DNA end-interaction are inefficient in generating the dimer complex that is requisite for NHEJ. In support of this idea, mutations that promote formation of this dimer partially rescue the severe cellular phenotypes associated with mutation of the DEB helix.
- 13 December 2023
- Published by Springer Nature in Research Square
Open AccessUnravelling the complexities of DNA-PK activation by structure-based mutagenesis.
It has been known for decades that the DNA-dependent protein kinase (DNA-PK) is only an active serine/threonine protein kinase when it is bound to a DNA double-stranded end; still, the molecular details of how this activation is achieved have remained elusive. The recent surge in structural information for DNA-PK complexes has provided valuable insights into the process of DNA end recognition by DNA-PK. A particularly intriguing feature of this kinase is a region of the protein that can transition from a seemingly structurally disordered state to a single alpha-helix that traverses down the DNA binding cradle. The DNA-PK bound DNA end of the DNA substrate engages with and appears to split around this helix which has been named the DNA End Blocking helix (DEB). Here a mutational approach is utilized to clarify the role of the DEB, and how DNA ends activate the enzyme. Our data suggest two distinct methods of kinase activation that is dependent on the DNA end chemistry. If the DNA end can split around the helix and stabilize the interaction between the DNA end and the DEB with a recently defined Helix-Hairpin-Helix (HHH) motif, the kinase forms an end-protection monomer that is active towards DNA-PK's many substrates. But if the DNA end cannot stably interact with the DEB [because of the DNA end structure, for instance hairpins, or because the DEB has been disrupted by mutation], the kinase is only partially activated, resulting in specific autophosphorylations of the DNA-PK monomer that allows nucleolytic end-processing. We posit that mutants that disrupt the capacity to stably generate the DEB/HHH DNA end-interaction are inefficient in generating the dimer complex that is requisite for NHEJ. In support of this idea, mutations that promote formation of this dimer partially rescue the severe cellular phenotypes associated with mutation of the DEB helix.
- 31 January 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (5) , 698-714.e4
Two distinct long-range synaptic complexes promote different aspects of end processing prior to repair of DNA breaks by non-homologous end joining
- 31 January 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (5) , 698-714.e4
Two distinct long-range synaptic complexes promote different aspects of end processing prior to repair of DNA breaks by non-homologous end joining
- Open Access
- 20 October 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (19) , 11058-11071
Catalytically inactive DNA ligase IV promotes DNA repair in living cells
DNA double strand breaks (DSBs) are induced by external genotoxic agents (ionizing radiation or genotoxins) or by internal processes (recombination intermediates in lymphocytes or by replication errors). The DNA ends induced by these genotoxic processes are often not ligatable, requiring potentially mutagenic end-processing to render ends compatible for ligation by non-homologous end-joining (NHEJ). Using single molecule approaches, Loparo et al. propose that NHEJ fidelity can be maintained by restricting end-processing to a ligation competent short-range NHEJ complex that ‘maximizes the fidelity of DNA repair’. These in vitro studies show that although this short-range NHEJ complex requires DNA ligase IV (Lig4), its catalytic activity is dispensable. Here using cellular models, we show that inactive Lig4 robustly promotes DNA repair in living cells. Compared to repair products from wild-type cells, those isolated from cells with inactive Lig4 show a somewhat increased fraction that utilize micro-homology (MH) at the joining site consistent with alternative end-joining (a-EJ). But unlike a-EJ in the absence of NHEJ, a large percentage of joints isolated from cells with inactive Lig4 occur with no MH – thus, clearly distinct from a-EJ. Finally, biochemical assays demonstrate that the inactive Lig4 complex promotes the activity of DNA ligase III (Lig3).
- 20 October 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (19) , 11058-11071
Open AccessCatalytically inactive DNA ligase IV promotes DNA repair in living cells
DNA double strand breaks (DSBs) are induced by external genotoxic agents (ionizing radiation or genotoxins) or by internal processes (recombination intermediates in lymphocytes or by replication errors). The DNA ends induced by these genotoxic processes are often not ligatable, requiring potentially mutagenic end-processing to render ends compatible for ligation by non-homologous end-joining (NHEJ). Using single molecule approaches, Loparo et al. propose that NHEJ fidelity can be maintained by restricting end-processing to a ligation competent short-range NHEJ complex that ‘maximizes the fidelity of DNA repair’. These in vitro studies show that although this short-range NHEJ complex requires DNA ligase IV (Lig4), its catalytic activity is dispensable. Here using cellular models, we show that inactive Lig4 robustly promotes DNA repair in living cells. Compared to repair products from wild-type cells, those isolated from cells with inactive Lig4 show a somewhat increased fraction that utilize micro-homology (MH) at the joining site consistent with alternative end-joining (a-EJ). But unlike a-EJ in the absence of NHEJ, a large percentage of joints isolated from cells with inactive Lig4 occur with no MH – thus, clearly distinct from a-EJ. Finally, biochemical assays demonstrate that the inactive Lig4 complex promotes the activity of DNA ligase III (Lig3).